| Can we face the challenge of expanding use of intravenous immunoglobulin in neurology? | |
| | |
MedLine Citation:
|
PMID: 20085560 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The use of high-dose polyclonal intravenous immunoglobulin (IVIG) in the treatment of autoimmune neurological diseases has expanded over the last decade. Based on controlled clinical trials IVIG can be considered currently as the first-line treatment in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, and it may be used as a rescue therapy in worsening myasthenia gravis. IVIG is a second-line therapy in dermatomyositis, stiff-person syndrome and pregnancy-associated or postpartum relapses of multiple sclerosis. Although the biological efficacy of IVIG is due to multiple effects on the immune system, many mechanisms are still unknown. The awareness of risks and complications of IVIG therapy has increased, but severe side effects are still considered rare. Due to increasing costs of this treatment, careful selection of patients who will benefit from IVIG is extremely important. |
| | |
Authors:
|
I Elovaara; A Hietaharju |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Acta neurologica Scandinavica Volume: 122 ISSN: 1600-0404 ISO Abbreviation: Acta Neurol. Scand. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370336 Medline TA: Acta Neurol Scand Country: Denmark |
Other Details:
|
Languages: eng Pagination: 309-15 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 The Authors. Journal compilation © 2010 Blackwell Munksgaard. |
Affiliation:
|
Department of Neurology, Tampere University Hospital and Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland. irina.elovaara@uta.fi |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's di...
Next Document: Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease.